CannabinoidNCT07582445
Perioperative Prospective Follow Up Of Cannabis Consumers and Discrepancy Use
An observational study of Cannabinoid and Discrepancy With Clinical Examination, run by Hadassah Medical Organization at 1 site in Israel.
Trial summary
This study includes a prospective non interventional study that aims to asses the prevalence of cannabis use among patients undergoing elective surgery and evaluates its impact on perioperative outcomes, including pain, opioid consumption, nausea, anxiety, and sleep disturbances. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Cannabinoid, Discrepancy With Clinical Examination
- What is being tested?
- This study is non interventional and will only include filling in questionnaires and providing blood and urine sample
- How many people
- 600 participants
- Where
- 1 siteIsrael
- Study dates
- 6 May 2026to 10 Dec 2027
- How long will I take part?
- 1 Month
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: The study population will consist of patients scheduled to undergo elective surgery. This will include individuals who regularly use cannabis, as well as a matched control cohort with similar demographics who do not use cannabis.
Who may be able to join
- Patients who use cannabis and are scheduled to undergo elective surgery.
- A matched control cohort of patients with similar demographics who are also scheduled for elective surgery.
Who cannot join
- None
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Perioperative Prospective Follow Up Of Cannabis Consumers
This study includes a prospective non interventional study that aims to asses the prevalence of cannabis use among patients undergoing elective surgery and evaluates its impact on perioperative outcomes, including pain, opioid consumption, nausea, anxiety, and sleep disturbances. A matched control cohort will provide comparative data. Discrepancies between self-reported and objectively measured cannabis use will be assessed using blood samples and urine samples. Participants will be requested to complete preoperative and postoperative questionnaires on days 1, 2, 3, 7, and 30 to monitor cannabis use and perioperative symptoms. This study aims to clarify the perioperative effects of cannabis use and the accuracy of patient-reported consumption.
Read the detailed description
This study aims to assess the proportion of cannabis users who undergo surgery. In addition, we seek to evaluate whether chronic cannabis use affects the perioperative period. Specifically, we will examine whether cannabis use around the time of surgery influences levels of pain, opioid consumption, nausea, anxiety, and sleep disturbances.
A matched control cohort with similar patient characteristics will be used for comparison.
Another key objective is to assess discrepancies between patients' self-reported cannabis use and their actual usage. This will be evaluated by comparing patient-reported data to objective measures such as blood test results and documented cannabis levels in medical records. We hypothesize that patients tend to underreport their cannabis use relative to the levels detected through clinical testing.
Following signing an informed consent, study participants will be asked to complete a preoperative questionnaire to assess their cannabis consumption habits.
Prior to anesthesia adminsatration, a 6 cc blood sample will be collected from the patient's intravenous line. This sample will be used to measure cannabis levels in the blood, allowing for a comparison between self-reported cannabis use and actual detected levels. The sample will be immediately labeled with a unique serial number in the operating room. After plasma separation via centrifugation, the sample will be frozen for later analysis using high-performance liquid chromatography (HPLC . All samples will be deidentified to external personal.
Following surgery, participants will be asked to complete questions postoperatively up to 7 days. These follow-ups will gather information on any changes in cannabis use as well as symptoms such as pain intensity, nausea, sleep quality, and use of rescue medications.
- Conditions
- Cannabinoid, Discrepancy With Clinical Examination
- Being tested
- This study is non interventional and will only include filling in questionnaires and providing blood and urine sample
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
This study is non interventional and will only include filling in questionnaires and providing blood and urine sampleOther
urine sample
| Study group | Role | What they receive |
|---|---|---|
| Study cohort: patients undergoing elective surgery who use cannabis. | Control cohort: patients undergoing elective surgery who do not regularly use cannabis. Receives: Other: This study is non interventional and will only include filling in questionnaires and providing blood and urine sample | |
| control group | Patients undergoing elective surgery who do not use cannabis regularly Receives: Other: This study is non interventional and will only include filling in questionnaires and providing blood and urine sample |
What is being measured
The primary outcome is the main question the study is designed to answer.
discrepancy percentage between reported cannabis users and actual cannabis usage among patients undergoing elective surgery.
Measured: up to 7 days
Use of Cannabis
Doasge Use of Cannabis
Measured: up to 7 days postopertively
Secondary outcomes (1)
Pain levels during surgery as assesed using VAS
We aim to assess whether pain levels during surgery are affected by cannabis use of the VAS questionaire
Measured: up to 7 days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 May 2026
- Study start6 May 2026
- Primary completion10 Jul 2026 (estimated)
- Study completion10 Dec 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for CannabinoidStudies of the same condition, open and under way.
- More trials run by Hadassah Medical OrganizationThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Prospective
- Enrolment
- 600 participants (estimated)
- Target duration
- 1 Month
Sponsor and investigators
- Lead sponsor
- Hadassah Medical Organization
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Elyad Davidson, Hadassah Medical Organization
- Investigators
- Elyad Davidson, MD, Principal investigator, Hadassah medical center/ Hebrew univeristy
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07582445
- Sponsor's protocol ID
- 0001-25-HMO
- Status last verified
- May 2026
- First submitted
- 7 Sep 2025
- Last updated
- 12 May 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 12 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Perioperative Prospective Follow Up Of Cannabis Consumers
- ClinicalTrials.gov ID
- NCT07582445
- Acronym / sponsor ID
- 0001-25-HMO
- Conditions
- Cannabinoid, Discrepancy With Clinical Examination
- Study type
- Observational
- Recruitment status
- Active, not recruiting
- Enrolment
- 600 participants (estimated)
- Lead sponsor
- Hadassah Medical OrganizationUniversity, hospital or other
- Study start
- 6 May 2026 (actual)
- Primary completion
- 10 Jul 2026 (estimated)
- Study completion
- 10 Dec 2027 (estimated)
- First posted
- 12 May 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study includes a prospective non interventional study that aims to asses the prevalence of cannabis use among patients undergoing elective surgery and evaluates its impact on perioperative outcomes, including pain, opioid consumption, nausea, anxiety, and sleep disturbances. A matched control cohort will provide comparative data. Discrepancies between self-reported and objectively measured cannabis use will be assessed using blood samples and urine samples. Participants will be requested to complete preoperative and postoperative questionnaires on days 1, 2, 3, 7, and 30 to monitor cannabis use and perioperative symptoms. This study aims to clarify the perioperative effects of cannabis use and the accuracy of patient-reported consumption.
Detailed description
This study aims to assess the proportion of cannabis users who undergo surgery. In addition, we seek to evaluate whether chronic cannabis use affects the perioperative period. Specifically, we will examine whether cannabis use around the time of surgery influences levels of pain, opioid consumption, nausea, anxiety, and sleep disturbances.
A matched control cohort with similar patient characteristics will be used for comparison.
Another key objective is to assess discrepancies between patients' self-reported cannabis use and their actual usage. This will be evaluated by comparing patient-reported data to objective measures such as blood test results and documented cannabis levels in medical records. We hypothesize that patients tend to underreport their cannabis use relative to the levels detected through clinical testing.
Following signing an informed consent, study participants will be asked to complete a preoperative questionnaire to assess their cannabis consumption habits.
Prior to anesthesia adminsatration, a 6 cc blood sample will be collected from the patient's intravenous line. This sample will be used to measure cannabis levels in the blood, allowing for a comparison between self-reported cannabis use and actual detected levels. The sample will be immediately labeled with a unique serial number in the operating room. After plasma separation via centrifugation, the sample will be frozen for later analysis using high-performance liquid chromatography (HPLC . All samples will be deidentified to external personal.
Following surgery, participants will be asked to complete questions postoperatively up to 7 days. These follow-ups will gather information on any changes in cannabis use as well as symptoms such as pain intensity, nausea, sleep quality, and use of rescue medications.
Study design
- Observational model
- Case-control
- Time perspective
- Prospective
- Target follow-up
- 1 Month
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Study cohort: patients undergoing elective surgery who use cannabis. | – | Other: This study is non interventional and will only include filling in questionnaires and providing blood and urine sampleControl cohort: patients undergoing elective surgery who do not regularly use cannabis. |
| control group | – | Other: This study is non interventional and will only include filling in questionnaires and providing blood and urine samplePatients undergoing elective surgery who do not use cannabis regularly |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- The study population will consist of patients scheduled to undergo elective surgery. This will include individuals who regularly use cannabis, as well as a matched control cohort with similar demographics who do not use cannabis.
Key inclusion criteria (2 listed)
- Patients who use cannabis and are scheduled to undergo elective surgery.
- A matched control cohort of patients with similar demographics who are also scheduled for elective surgery.
Key exclusion criteria (1 listed)
- None
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| This study is non interventional and will only include filling in questionnaires and providing blood and urine sampleurine sample | Other | Study cohort: patients undergoing elective surgery who use cannabis., control group |
Primary outcome
discrepancy percentage between reported cannabis users and actual cannabis usage among patients undergoing elective surgery.
Time frame: up to 7 days
Use of Cannabis
Time frame: up to 7 days postopertively
Doasge Use of Cannabis
1 secondary outcome
Pain levels during surgery as assesed using VAS
Time frame: up to 7 days
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 12 May 2026.
- Individual participant dataSharing planned: Undecided
Related trials for Cannabinoid
RecruitingPhase 3
Nabilone for Agitation Blinded Intervention Trial
Alzheimer Disease, Agitation
RecruitingObservational study
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
Breast Carcinoma, Colorectal Carcinoma
Not yet recruitingPhase 1
Novel endOvascular Therapy With beVAcizumab and Cannabinoids for Glioblastoma
GBM
RecruitingObservational study
Lemborexant vs Clonidine vs Sedatives to Treat Insomnia in Chronic Pain Patients
Chronic Insomnia, Chronic Pain
Enrolling by invitationObservational study
Cannabis, Neuroinflammation, and Suicidal Ideation: A Supplemental Brain Imaging Study
PTSD, Suicidal Thoughts and Behaviors
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Elyad Davidson, MD principal investigator
Hadassah medical center/ Hebrew univeristy
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Cannabinoid and Discrepancy With Clinical Examination, run by Hadassah Medical Organization at 1 site in Israel.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 12 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Israel. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
discrepancy percentage between reported cannabis users and actual cannabis usage among patients undergoing elective surgery. (time frame: up to 7 days). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 May 2026.